Validated GC–MS analysis for the determination of residual fentanyl in applied Durogesic® reservoir and Durogesic® D-Trans® matrix transdermal fentanyl patches - ScienceDirect
Por um escritor misterioso
Descrição
FENTANYL TRANSDERMAL SYSTEM 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr CII Full Prescribing Information Rx only FOR USE IN OPIOID-TOLERANT PATIENTS ONLY
Validated GC–MS analysis for the determination of residual fentanyl in applied Durogesic® reservoir and Durogesic® D-Trans® matrix transdermal fentanyl patches - ScienceDirect
Predicting transdermal fentanyl delivery using physics-based simulations for tailored therapy
Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches
Transdermal fentanyl matrix patches Matrifen® and Durogesic® DTrans® are bioequivalent - ScienceDirect
Toxicological implications of the delivery of fentanyl from gel extracted from a commercial transdermal reservoir patch - ScienceDirect
Transdermal Matrix Fentanyl Membrane Patch (Matrifen®)
Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches
Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches
Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches
de
por adulto (o preço varia de acordo com o tamanho do grupo)